Adjunct for CNS disease prevention in non-Hodgkin's lymphoma

This clinical indication refers to prophylactic intervention administered alongside frontline systemic therapy to prevent secondary central nervous system (CNS) dissemination or relapse in patients with non-Hodgkin lymphoma This preventive strategy specifically targets patient populations with high-grade or aggressive histological subtypes—such as Burkitt lymphoma, lymphoblastic lymphoma, and high-risk diffuse large B-cell lymphoma—or those harboring clinical risk factors like elevated lactate d...

This clinical indication refers to prophylactic intervention administered alongside frontline systemic therapy to prevent secondary central nervous system (CNS) dissemination or relapse in patients with non-Hodgkin lymphoma The condition involves the hematogenous or contiguous seeding of malignant lymphoid cells into the leptomeninges, cerebrospinal fluid, or brain and spinal cord parenchyma, a complication historically associated with rapid clinical decline and poor overall survival Pathophysio...

The condition involves the hematogenous or contiguous seeding of malignant lymphoid cells into the leptomeninges, cerebrospinal fluid, or brain and spinal cord parenchyma, a complication historically associated with rapid clinical decline and poor overall survival

The condition involves the hematogenous or contiguous seeding of malignant lymphoid cells into the leptomeninges, cerebrospinal fluid, or brain and spinal cord parenchyma, a complication historically associated with rapid clinical decline and poor overall survival This preventive strategy specifically targets patient populations with high-grade or aggressive histological subtypes—such as Burkitt lymphoma, lymphoblastic lymphoma, and high-risk diffuse large B-cell lymphoma—or those harboring clin...

Pathophysiologically, the blood-brain and blood-cerebrospinal fluid barriers shield occult micrometastases from standard systemic immunochemotherapy, creating a pharmacologic sanctuary that requires specialized central-nervous-system-directed agents to eliminate subclinical disease